Literature DB >> 3368198

DNA distributions in human normal, precancerous and cancerous breast tissue. II. Differences in heparin mediated changes in DNA distributions.

H Weiss1, D Kunde, B Streller.   

Abstract

DNA distributions were recorded flow cytometrically (FCM) in human normal, precancerous (P1 characterized by ductal hyperplasia and/or lobular hyperplasia, and P2 characterized by carcinomata lobularia in situ and intraductal carcinoma) and malignant breast tissues. Heparin, a polyanion, mediated two changes: (a) a time-dependent increase in fluorescence intensity (IFI) considered to be inversely proportional to the proliferative activity. IFI was significantly lower in carcinomas than in P2, in normal and in P1 tissues; it identified a highly and a poorly heparin-sensitive subgroup of carcinomas, which differed in respect to histological type and tumor stage distribution; (b) a time-dependent increase in the percentage of recorded DNA aneuploid cells (IAC) at the expense of DNA diploid cells in mixed cell population. IAC is considered to correspond to cell membrane permeability. DNA aneuploid cell populations homogeneous in respect to DNA - index (DI) seem to be heterogeneous in respect to cell membrane function. Duct carcinomas showed significantly higher IAC than lobular carcinomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3368198     DOI: 10.1159/000226565

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Mitotic rate, DNA distribution, and chromatin in situ sensitivity to heparin in breast cancer.

Authors:  H Weiss; H P Brasching; A Bock; F Mauthner; U Peek
Journal:  Breast Cancer Res Treat       Date:  1990-07       Impact factor: 4.872

2.  Flow-cytometrically monitored chromatin in situ testing in the breast cell line H184A1N4.

Authors:  H Weiss; P Langen; U Nitschke; I Thun
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

3.  Prevalence of aneuploidy, overexpressed ER, and overexpressed EGFR in random breast aspirates of women at high and low risk for breast cancer.

Authors:  C J Fabian; C Zalles; S Kamel; B F Kimler; R McKittrick; A S Tranin; S Zeiger; W P Moore; R S Hassanein; C Simon
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.